Clinical Trial Update: Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating ribavirin plus low-dose cytarabine for acute myeloid leukemia has completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Low-dose cytarabine (Cytarabine (low-dose))
• Ribavirin (ribavirin)

Snippet

Sponsor: Jewish General Hospital | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-01-30